The FDA appears to be reevaluating its approach to drug reviews, with some outlets suggesting a focus on psychedelic drugs for mental health treatment. There are reports of the FDA moving to fast-track reviews of certain drugs, although it is unclear if this is a broader policy shift or limited to specific treatments. The situation is uncertain, with some reports mentioning psychedelic drugs, while others reference vaccine approvals and unrelated treatments.